Loading...
Bilateral Trade Intelligence · $9.5M Total Trade · 81 Foreign Suppliers · 48 Indian Buyers · DGFT Verified · Updated March 2026
India imported $9.5M worth of pharmaceutical formulations from Japan across 602 verified shipments, from 81 foreign suppliers to 48 Indian buyers. The top suppliers are THOMAS TRADING CO. LTD ($1.0M) and EISAI CO. LTD. ($943.8K). The leading products are Serum ($6.6M) and Lenvatinib ($1.2M). Average shipment value: $15.8K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Serum | $6.6M | 69.3% |
| 2 | Lenvatinib | $1.2M | 12.4% |
| 3 | Probiotics | $1.0M | 11.0% |
| 4 | Plasma | $133.5K | 1.4% |
| 5 | Sodium | $120.4K | 1.3% |
| 6 | Pomalidomide | $107.4K | 1.1% |
| 7 | Trastuzumab | $75.6K | 0.8% |
| 8 | Gefitinib | $42.0K | 0.4% |
| 9 | Vaccine | $31.5K | 0.3% |
| 10 | Ofloxacin | $18.3K | 0.2% |
| 11 | Levofloxacin | $18.3K | 0.2% |
| 12 | Tofacitinib | $16.6K | 0.2% |
| 13 | Sitagliptin | $15.7K | 0.2% |
| 14 | Ibrutinib | $15.5K | 0.2% |
| 15 | Calcium | $14.2K | 0.1% |
India imports 20+ pharmaceutical formulations from Japan with a combined trade value of $9.5M. Key products include Serum ($6.6M), Lenvatinib ($1.2M), Probiotics ($1.0M), Plasma ($133K), Sodium ($120K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 602 verified Indian Customs (DGFT) shipment records.
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Japan and India has experienced significant growth over the past decade. In 2022, India imported pharmaceutical products from Japan valued at approximately $9.5 million USD, distributed across 602 shipments from 81 Japanese suppliers to 48 Indian buyers. This reflects a robust and expanding trade relationship, underscoring Japan's increasing role in meeting India's pharmaceutical needs.
The average shipment value stands at $16,000 USD, indicating a diverse range of product types and quantities. The top three Japanese suppliers—THOMAS TRADING CO. LTD., EISAI CO. LTD., and THOMAS TRADING CO LIMITED—have collectively contributed significantly to this trade, highlighting the importance of these partnerships in facilitating the flow of pharmaceutical goods.
Japan's contribution to India's pharmaceutical imports is notable, with a total import value of $9.5 million USD in 2022. The primary categories imported include serum, lenvatinib, and probiotics, which together account for a substantial portion of the total import value. This indicates that Japan plays a crucial role in supplying specialized and high-quality pharmaceutical products to the Indian market.
The diversity in product types—from biologics like serum and lenvatinib to probiotics—demonstrates Japan's capacity to meet various therapeutic needs within India. This range not only addresses existing medical requirements but also supports the advancement of healthcare by introducing innovative treatments and formulations.
These are the top pharmaceutical products exported from India to Japan, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Japan buyers, regulatory requirements, and logistics for that specific product corridor. Products include Serum ($6.6M), Lenvatinib ($1.2M), Probiotics ($1.0M), Plasma ($133K), Sodium ($120K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
81 Indian pharmaceutical companies export finished formulations to Japan. Leading exporters include Thomas Trading Co. Ltd, Eisai Co. Ltd., Thomas Trading Co Limited, Thomas Trading Co. Limited. The top exporter accounts for 10.8% of total India–Japan pharma exports. Source: Indian Customs (DGFT).
48 companies in Japan import pharmaceutical formulations from India. Top buyers include Tablets (india) Ltd, Eisai Pharmaceuticals India Private Limited, Allianz Biosciences Private Limited, Tablets India Limited. The largest buyer accounts for 111.2% of India–Japan pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, several key developments have influenced the pharmaceutical trade between Japan and India. The Central Drugs Standard Control Organisation (CDSCO) has implemented policy changes aimed at streamlining the import process, enhancing efficiency, and ensuring product safety. Additionally, trade agreements and regulatory harmonization efforts have been undertaken to facilitate smoother transactions and foster stronger bilateral ties in the pharmaceutical sector.
These initiatives reflect a concerted effort by both nations to strengthen their pharmaceutical trade relationship, ensuring that high-quality medicines are accessible to the Indian population while maintaining rigorous safety and efficacy standards.
Registration process, GMP requirements, import documentation
For Japanese pharmaceutical companies aiming to export products to India, obtaining approval from the Central Drugs Standard Control Organisation (CDSCO) is mandatory. The process involves several key steps:
1. Application Submission: An authorized Indian agent must submit the application on behalf of the Japanese manufacturer through the CDSCO's online portal, SUGAM. This includes providing detailed information about the product and manufacturing processes.
2. Documentary Requirements: Essential documents include a Power of Attorney from the manufacturer, a Site Master File detailing the manufacturing facility, a Plant Master File, and a Free Sale Certificate from the country of origin.
3. Review and Approval: CDSCO reviews the application and may conduct inspections to verify compliance with Indian standards. Upon satisfactory evaluation, a registration certificate is issued, authorizing the import and sale of the product in India.
The timeline for this process can vary, but it typically ranges from several months to a year, depending on the complexity of the product and the completeness of the application.
India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards to ensure the quality and safety of imported pharmaceutical products. Manufacturers must provide evidence of GMP compliance, which may include certifications from recognized authorities and detailed documentation of manufacturing processes.
The CDSCO may conduct inspections to verify adherence to these standards. Additionally, products must meet the World Health Organization's (WHO) prequalification criteria, ensuring they are suitable for procurement by international agencies and meet global quality standards.
Importing pharmaceutical products into India from Japan requires several key documents:
1. Import License (Form 10): This license authorizes the import of drugs into India and is issued by the CDSCO.
2. Registration Certificate: Issued by CDSCO, this certificate confirms that the imported product has been approved for sale in India.
3. No Objection Certificate (NOC): This certificate is required for certain products, such as blood products, to ensure they meet Indian standards.
4. Test License: For products intended for testing or clinical trials, a test license is necessary.
5. Customs Procedures: Compliance with Indian customs procedures is essential, including proper labeling, packaging, and documentation to facilitate smooth clearance at ports.
Ensuring all documentation is accurate and complete is crucial to avoid delays and ensure compliance with Indian regulations.
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical imports from Japan are predominantly in the biologics and specialty products categories. Serum, accounting for 69.3% of the total import value, and lenvatinib, comprising 12.4%, are the leading products. These products are essential for treating various medical conditions, including cancers and other serious diseases, highlighting the critical role of Japanese pharmaceutical exports in addressing India's healthcare needs.
The presence of probiotics, plasma, and other specialized products further indicates the diversity and specialization of Japanese pharmaceutical offerings, catering to a wide range of therapeutic areas and patient requirements.
Japan's pharmaceutical exports to India include innovative drugs and novel formulations not manufactured domestically. Lenvatinib, a targeted cancer therapy, exemplifies such products, offering advanced treatment options for patients. The importation of these specialized products underscores the importance of international collaboration in providing cutting-edge medical treatments to the Indian population.
India's importation of pharmaceutical products from Japan is driven by several factors:
1. Patent Protection: Imported drugs often include patented medications that are not yet available in the domestic market, providing access to the latest treatments.
2. Technology Gaps: Japan's advanced pharmaceutical technologies fill gaps in India's manufacturing capabilities, particularly in producing complex biologics and specialty drugs.
3. Quality Requirements: Japanese pharmaceutical products are renowned for their high quality and adherence to international standards, meeting the stringent requirements of the Indian market.
4. Disease Burden: The prevalence of certain diseases in India necessitates the importation of specialized treatments that are not available locally.
These factors collectively contribute to the sustained demand for Japanese pharmaceutical imports in India.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
1. Most Favored Nation (MFN) Tariff Rates: These rates are applied to imports from countries with which India has trade agreements, ensuring non-discriminatory treatment.
2. Basic Customs Duty: This duty is levied on imported goods, with rates varying based on product classification and trade agreements.
3. Integrated Goods and Services Tax (IGST): IGST is applicable on imported goods, ensuring a uniform tax structure across the country.
4. Health Cess: A health cess is imposed on certain imported pharmaceutical products to fund health initiatives within the country.
These tariffs and taxes are subject to change based on government policies and trade negotiations.
India and Japan have engaged in trade agreements aimed at enhancing bilateral trade, including the Comprehensive Economic Partnership Agreement (CEPA). These agreements often provide preferential duty rates and facilitate smoother trade processes. Additionally, India's participation in the Regional Comprehensive Economic Partnership (RCEP) and other bilateral negotiations may further influence trade dynamics and tariff structures.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations receive patent protection. Compulsory licensing provisions allow the government to grant licenses to third parties to produce patented products under certain conditions, such as public health emergencies. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported ones, to ensure affordability and accessibility for the Indian population.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical products from Japan to India are primarily transported via sea and air routes. Major sea routes include shipments from Japanese ports like Yokohama and Kobe to Indian ports such as Mumbai and Chennai. Air freight is also utilized, with products flown from airports like Tokyo Narita to major Indian airports, including Delhi and Mumbai. Transit times vary, with sea shipments taking approximately 10-14 days and air shipments around 5-7 days, depending on the specific ports and logistics arrangements.
Key Japanese export ports handling pharmaceutical shipments include Yokohama and Kobe, which are equipped with facilities to handle pharmaceutical goods efficiently. In India, major import ports include Mumbai, Chennai, and Delhi, which
India exported pharmaceuticals worth $9.5M to Japan across 602 verified shipments.
1. THOMAS TRADING CO. LTD — $1.0M. 2. EISAI CO. LTD. — $943.8K. 3. THOMAS TRADING CO LIMITED — $450.5K. Total: 81 suppliers.
1. TABLETS (INDIA) LTD — $10.6M. 2. EISAI PHARMACEUTICALS INDIA PRIVATE LIMITED — $1.2M. 3. ALLIANZ BIOSCIENCES PRIVATE LIMITED — $910.6K. 48 buyers total.
1. Serum ($6.6M, 69.3%); 2. Lenvatinib ($1.2M, 12.4%); 3. Probiotics ($1.0M, 11.0%); 4. Plasma ($133.5K, 1.4%); 5. Sodium ($120.4K, 1.3%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $9.5M corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$15.8K per consignment across 602 shipments.
81 Indian companies. Largest: THOMAS TRADING CO. LTD with $1.0M.
TransData Nexus covers 81 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 602 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
81 Exporters
48 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists